Innovent Reports the First Patient Dosing of IBI112 in a P-II Clinical Study for the Treatment of Moderate-to-Severe Active Ulcerative Colitis
Shots:
- The first patient has been dosed in a P-II study evaluating IBI112 (anti-IL-23p19 mAb) in 150 patients with mod. to sev. active UC
- The primary objective of the study is to evaluate the efficacy, safety, PK & immunogenicity of IBI112 induction and maintenance therapy in patients with active UC. In the P-I study, IBI112 showed favorable safety and tolerability profiles and initially showed promise for a longer dosing interval & more patient-friendly treatment regimen
- The therapy offers an effective treatment option for IBD including UC & other autoimmune diseases. In the preclinical study, the therapy demonstrated that it has a clear target and well-elucidated MoA along with a significant anti-inflammatory effect
Ref: PRNewswire | Image: Innovent
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
